Charles River Laboratories International (NYSE:CRL) Shares Down 3.3% - Here's Why

Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report)'s share price traded down 3.3% during trading on Monday . The company traded as low as $146.26 and last traded at $149.36. 130,913 shares were traded during mid-day trading, a decline of 87% from the average session volume of 1,034,676 shares. The stock had previously closed at $154.48.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Evercore ISI lifted their target price on Charles River Laboratories International from $170.00 to $180.00 and gave the stock an "outperform" rating in a report on Wednesday, July 9th. Redburn Atlantic upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and dropped their target price for the stock from $188.00 to $182.00 in a report on Friday, May 23rd. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. Mizuho dropped their target price on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a report on Wednesday, April 9th. Finally, Robert W. Baird lifted their target price on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $174.54.

Charles River Laboratories International Trading Up 5.9%

The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. The stock has a 50-day simple moving average of $149.28 and a two-hundred day simple moving average of $150.23. The firm has a market capitalization of $8.74 billion, a P/E ratio of -273.74, a price-to-earnings-growth ratio of 5.68 and a beta of 1.49.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. The business had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. Charles River Laboratories International's revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the company posted $2.27 EPS. On average, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the transaction, the executive vice president directly owned 19,513 shares of the company's stock, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 1.30% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in Charles River Laboratories International by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company's stock valued at $1,136,938,000 after buying an additional 60,497 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Charles River Laboratories International by 5.1% in the first quarter. Wellington Management Group LLP now owns 4,285,012 shares of the medical research company's stock worth $644,980,000 after buying an additional 208,586 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC boosted its stake in shares of Charles River Laboratories International by 8.0% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,950,273 shares of the medical research company's stock worth $293,555,000 after buying an additional 144,732 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Charles River Laboratories International by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company's stock worth $227,042,000 after buying an additional 14,787 shares during the last quarter. Finally, Invesco Ltd. boosted its position in Charles River Laboratories International by 7.2% during the first quarter. Invesco Ltd. now owns 1,108,358 shares of the medical research company's stock worth $166,830,000 after purchasing an additional 74,178 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).